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**Abstract**

CINP is a leading organization in the field of CNS drugs. As Public Private Partnerships for CNS drug innovation activity, we have discussed in Japan on three topics 1. Imaging biomarkers, 2. Stratification factors, 3. How to share the clinical study data with Academia, Industry and Regulators. Working group 1 focused on imaging biomarkers those can be useful for decision making in drug development. The idea of three pillars to ensure the steps to get clinical POC has been reported form Pfizer. Pillar 1 means the evidence reaching the target site, pillar 2 means the evidence of binding to the pharmacological target and pillar 3 means the evidence of pharmacological action in the brain. The imaging biomarker can be used whether the candidate drug fulfill pillar 2, using receptor occupancy. Using common terminology to express the developing stage would be useful in PPP setting, since different company used different terminology in each company. During our discussion, we thought more precise classification would be needed to explain the stage of the candidate drugs. We propose tier as an alternative of pillar, \[Tier 1;target exposure, Tier 2; target binding/engagement, Tier 3a; mechanism-related change, Tier 3b; functional modulation, Tier 4; patient stratification, Tier 5 Disease-related change\]. Future needs of imaging biomarkers will be discussed in relation to the various imaging methods. Working group 2 focused stratification factors using the data on randomized double-blind clinical trials of conventional antidepressants vs placebo that have been conducted so far in Japan. Working group 3 focused how to share the clinical study data with Academia. Although majority of the pharmaceutical companies have disclosed not only an initiation/completion of their sponsored clinical trials but also the results through the public domain like clinical trial. gov., the details of the disclosed data have been limited. Working group 3 aimed to create a system to construct a database which unifies all clinical data obtained in the sponsored clinical studies in order to facilitate the pharmaceutical products of the next-generation.
